The FDA’s decision on Coherus BioSciences Inc.’s (CHRS) product candidate CHS-1701 is expected to be announced on June 9, 2017.CHS-1701 is a proposed biosimilar to Amgen's (AMGN) blockbuster Neulasta that was approved in 2002.Neulasta is used to treat neutropenia, a lack of certain white blood cells caused by cancer chemotherapy. The drug generated sales of $4.65 billion in sales for Amgen last year.On May 10, 2017, Amgen sued Coherus for allegedly infringing a patent covering Neulasta. In March of this year, Amgen had sued Coherus over Neulasta’s trade secrets.CHRS closed yesterday’s (May 24) trading at $20.40, down 6.64%.